On January 1st, 2020, Dr. Xin Du, former FDA senior reviewer, joined Evergreen Therapeutics Inc. as CEO to comprehensively lead the company's R&D. Dr. Du is a drug R&D expert with more than 20 years of biomedical background, and has a rich combination experience of FDA and industry in drug registration and drug development. Heis familiar with FDA and global regulations on drug development, production, quality management, clinical design and testing. At the same time, he has rich experience in drug R&D, and used to workin multiple multinational and Chinese pharmaceutical companies.Dr. Du Xin was a CMC reviewer in FDA and responsible for reviewing INDs and BLAs of biopharmaceuticals. After that he worked in multinational corporation at Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis,

On September 5th, 2019, Dr. Tao Du, the chairman of Evergreen Therapeutics Inc. , went to the famous Meakins-Christie Laboratories (MCL) of McGill University of Canada, known as the most prestigious respiratory disease institute in the world, for academic exchange activities with his team. Dr. Tao Du and team members discussed collaboration in respiratory disease research with Professor James G Martin, former director of MCL and current leader of internal medicine at McGill University School of Medicine. Both determined that research will be carried out in the fields of respiratory rare diseases and asthma and agreed to have in depth cooperation in clinical trials of respiratory rare diseases.Professor James G Martin has 35 years of clinical and scientific experience in the field